C WorldWide Group Holding A S reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 8.4% during the second quarter, Holdings Channel reports. The fund owned 250,231 shares of the company’s stock after selling 22,819 shares during the period. C WorldWide Group Holding A S’s holdings in Teva Pharmaceutical Industries Limited were worth $8,313,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. First Trust Advisors LP increased its position in shares of Teva Pharmaceutical Industries Limited by 10.5% in the second quarter. First Trust Advisors LP now owns 612,724 shares of the company’s stock worth $20,355,000 after buying an additional 58,414 shares during the last quarter. Boston Partners increased its position in shares of Teva Pharmaceutical Industries Limited by 32.6% in the second quarter. Boston Partners now owns 141,852 shares of the company’s stock worth $4,712,000 after buying an additional 34,846 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 7.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock worth $8,025,000 after buying an additional 17,116 shares during the last quarter. Wetherby Asset Management Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 7.5% in the second quarter. Wetherby Asset Management Inc. now owns 9,374 shares of the company’s stock worth $311,000 after buying an additional 653 shares during the last quarter. Finally, Trent Capital Management Inc. NC purchased a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter worth about $4,724,000. 56.27% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 17.19 on Friday. Teva Pharmaceutical Industries Limited has a 1-year low of $17.12 and a 1-year high of $55.39. The company has a 50 day moving average of $30.08 and a 200 day moving average of $31.67. The firm’s market capitalization is $17.47 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter last year, the business earned $1.25 earnings per share. The business’s quarterly revenue was up 12.9% on a year-over-year basis. Analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be given a $0.085 dividend. The ex-dividend date is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 1.98%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -18.95%.

WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/11/c-worldwide-group-holding-a-s-has-8-31-million-stake-in-teva-pharmaceutical-industries-limited-nyseteva.html.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a research report on Wednesday. Deutsche Bank AG reaffirmed a “buy” rating and issued a $28.00 price objective (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Jefferies Group LLC reaffirmed a “hold” rating and issued a $26.00 price objective (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price objective (down previously from $31.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Three analysts have rated the stock with a sell rating, nineteen have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.